March 2017, Volume 3, Issue 4

March 2017

Volume 3, Issue 4

This issue takes a look at diversity in the medical education system, provides a hematology drug pipeline update, and more.

Table of Contents

March 2017

Learning to Love Your Genome

Wednesday, March 1st, 2017
The daily circus of recent world events has left me wondering whether it is truly plausible that I share a genome with the other...

Not-So-NICE One

Wednesday, March 1st, 2017
In December 2016, we published an Online Exclusive item reporting on the United Kingdom’s National Institute for Health and Care Excellence’s (NICE) review of...

March 2017

Richard Pazdur Named Director of Oncology Center of Excellence, Be The Match Foundation® Receives...

Wednesday, March 1st, 2017
Stephen Gottschalk Joins St. Jude Children’s Research Hospital Stephen Gottschalk, MD, was named chair of the Department of Bone Marrow Transplantation and Cellular Therapy at...

ASH Joins Medical Groups in Expressing Concern Over Immigration Executive Order, and more

Wednesday, March 1st, 2017
ASH Joins Medical Groups in Expressing Concern Over Immigration Executive Order President Donald Trump’s executive order of January 27, which suspended “issuance of visas and...

March 2017

Diversity Evolution

Wednesday, March 1st, 2017
The United States is becoming more diverse. Is the medical education system adapting quickly enough? The need for increased diversity in the medical profession is...

Pulling Back the Curtain: Michael Linenberger, MD

Wednesday, March 1st, 2017
What was your first job? I grew up in rural Kansas, so there were plenty of opportunities for employment – most of them were in...

March 2017

How should this patient with severe macrocytic anemia be managed?

Wednesday, March 1st, 2017
This month, Ruben A. Mesa, MD, discusses treatment options for a 73-year-old male patient with severe macrocytic anemia. Also check out next month's clinical dilemma...

March 2017

HHS Issues Final Rule on Protecting Human Subjects in Research

Wednesday, March 1st, 2017
The U.S. Department of Health and Human Services (HHS) and 15 other federal agencies issued a final rule to update regulations regarding the use...

FDA Emphasizes Need for Phase III Clinical Trials

Wednesday, March 1st, 2017
A report issued by the FDA noted discrepancies between phase II and phase III drug trials, emphasizing the need for appropriate – and sometimes...

FDA Grants Ibrutinib Accelerated Approval for Marginal Zone Lymphoma

Wednesday, March 1st, 2017
The U.S. Food and Drug Administration (FDA) granted accelerated approval to ibrutinib for marginal zone lymphoma (MZL) following at least one prior anti-CD20-based therapy. The...

Vadastuximab Talirine in Higher-Risk MDS, Low-Dose Rituximab for Acquired TTP, and more

Wednesday, March 1st, 2017
ASH Clinical News' Associate Editors select clinical trials to keep an eye on in leukemia, bleeding disorders, and lymphoma & myeloma.David Steensma, MD Dana-Farber Cancer Institute Study...

Lenalidomide Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults

Wednesday, March 1st, 2017
Results from the Myeloma XI trial presented at the 2016 ASH Annual Meeting supported the use of lenalidomide as maintenance therapy for patients with...

Choosing Between Strategies for Managing Fetal or Neonatal Alloimmune Thrombocytopenia

Wednesday, March 1st, 2017
For women diagnosed with fetal and neonatal alloimmune thrombocytopenia (FNAIT), a noninvasive strategy of weekly intravenous immunoglobulin infusion (IVIg) and corticosteroids could help prevent...

Self-Reporting Significantly Overestimates Treatment Adherence in Pediatric Patients With Acute Lymphocytic Leukemia

Wednesday, March 1st, 2017
Maintenance therapy with oral 6-mercaptopurine (6MP) for pediatric patients with acute lymphocytic leukemia (ALL) is crucial for maintaining a durable remission, and poor adherence...

Radiation Dose and Use of Anthracyclines Increase Risk of Heart Failure in Hodgkin Lymphoma...

Wednesday, March 1st, 2017
Previous studies have linked mediastinal radiotherapy (RT) and/or anthracycline-containing chemotherapy with increased risk of coronary heart disease, valvular heart disease, and heart failure (HF)...

Investigating Clonal Dynamics of Different Mutations in Myelodysplastic Syndromes

Wednesday, March 1st, 2017
In a whole-exome sequencing (WES) and targeted deep sequencing study published in Nature Genetics, researchers identified several biomarkers that could improve diagnosis and therapy...

TP53 Mutation Status Predicts Response to Decitabine for Patients With Acute Myeloid Leukemia...

Wednesday, March 1st, 2017
Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who have unfavorable-risk cytogenetic abnormalities and TP53 mutations responded to treatment with decitabine, according...

March 2017

Early Studies Reveal Efficacy, Safety Concerns With Vadastuximab Talirine in Patients With Acute Myeloid...

Wednesday, March 1st, 2017
Early studies of vadastuximab talirine (33A) in patients with acute myeloid leukemia (AML) have shown preliminary efficacy, whether the drug has been used as...

Phase I Study Shows Venetoclax Active in Patients With Relapsed/Refractory Myeloma

Wednesday, March 1st, 2017
The B-cell lymphoma/leukemia-2 (BCL-2) inhibitor venetoclax may be a new option for patients with heavily treated multiple myeloma (MM), according to results from an...

Newly Approved Drugs: How to Use Them in Practice

Wednesday, March 1st, 2017
In 2016, the U.S. Food and Drug Administration (FDA) approved several new therapies for the treatment of hematologic disorders, marking several “firsts” for hematology,...

BLU-285 Shows Tolerable Safety, Early Clinical Activity in Patients With Advanced Systemic Mastocytosis

Wednesday, March 1st, 2017
BLU-285, an oral inhibitor of KIT D816V, is well tolerated and could alleviate symptom burden for patients with advanced systemic mastocytosis (SM), according to...

SHARE